The Impact of Transcatheter Aortic Valve Implantation on Right Ventricular Function  by Ayhan, Hüseyin et al.
Table 2. Vascular Access site complications according to VARC classiﬁcation
Vascular complication
Major 4/91 (4,4 %)
Minor 5/91 (5,5 %)
Bleeding complication
Life-threatenimg/disabling 5/91 (5,6 %)
Major 4/91 (4,5 %)
Minor 2/91 (2,2 %)
Table 1. Basal and procedural characteristics of patients
Table 1. Patients baseline characteristics (n ¼ 91)
Age (years), mean  SD 78,3  7,43
Men 28/91 (30.8 %)
Body mass index (kg/m2), mean  SD 28.3  8.6
New York Heart Association class III or IV 84/91 (92 %)
Logistic EuroSCORE, median 22,3  16,2
Society of Thoracic Surgeons score,
median
7,57  5,3
Peripheral vascular disease 30/91 (33.7 %)
Coronary artery disease 60/91 (67 %)
Previous percutaneous coronary
intervention
14/91 (16 %)
Previous cardiac surgery 36/91 (38 %)
Diyabetes mellitus 21/91 (23.6 %)
Current smoking 16/91 (18 %)
Access and closure strategy
Percutaneous 78/91 (85.7 %)
Surgical 13/91 (14.3 %)
Table 2. Right ventricular echocardiography parameters changing with TAVI
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Background and Aim: With the increase in life expectancy, the prevalence of aortic
stenosis (AS) has increased as well. Transcatheter aortic valve implantation (TAVI)
has been improved rapidly and become an important treatment option for inoperable
and high risk patients. While the impact ofsurgical aortic valve replacement (s-AVR)
or TAVI on the function of left ventricle has been studied with various imaging
modalities, little is known about the impact on right ventricular (RV) function. In the
current study, we evaluate the impact of TAVI on the RV function using conventional
echocardiographic parameters.
Methods: Echocardiography (Philips iE33) was performed prior to, immediately after,
and 1 month after valve implantation. RV function was assessed using: (1) tricuspid
annular plane systolic excursion (TAPSE), (2) RV Tissue Doppler Imaging (S’), (3)
the right ventricular systolic pressure (RVSP), (4) Fractional area change (FAC)
equation: FAC ¼ (end-diastolic area - end-systolic area)/ (end-diastolic area)x100. (5)
The RV ejection fraction (RVEF) is calculated using Eq. RV ejection fraction ¼(end-
diastolic volume-end-systolic volume)/(end-diastolic volume)  100. TAVI was
performed through subclavian artery in 2 patients and transfemoral artery in 40
patients. Edwards Sapien XT (Edwards Lifesciences, Irvine, CA, USA) valve was
used to all of the patients.
Results: 42 patients were performed TAVI between October 2012 and April 2013. Of
these 42 patients, 26 were female and 16 were male with a 78,2 years mean age. The
average valve area was determined as 0,6 cm2 and average mean gradient as 54,6
mmHg in echocardiography. The average Society of Thoracic Surgeons (STS) score
of the patients was 7,1 (co-morbidity as hematologic and cirrhosis, high risk according
to surgeon), mean logistic EuroScore was %21,8 and %87 of them were in moderate
and high risk groups according to SURTAVI risk model. The patients’ average mean
aortic valve gradient was 9,8 mmHg after the TAVI. No moderate or severe para-
valvular aortic regurgitation was detected. After the procedure, there were no
mortality, and 1 patient died of non–cardiac reasons within 30 days. Baseline, post-
TAVI and 1st month after TAVI, mean RVSP (PASP) was 46,2, 39,6 and 41,2 mmHgJACC Vol 62/18/Suppl C j October 26–29, 2013 j TSC Abstracts/ORArespectively (p:0,04). There was statistically signiﬁcant decrease RVSP with TAVI.
When evaluated either by TAPSE (p:0,03), RVEF (p:0,02) FAC (p:0,009) and RV
TDI S’ (p:0,008) RV function was improved statistically signiﬁcant with TAVI.
Conclusion: It has been demonstrated that right ventricular systolic dysfunction
develops soon after s-AVR. However, few studies have evaluated RV function in
patients who had undergone TAVI. This study indicates that an improvement in RV
function assessed by echocardiography and TDI could be seen already one month after
TAVI. We conclude that patients with severe AS and a high surgical risk proﬁle have
a favorable change in RV function immediately and one month after TAVI.LS C33
